EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Differential Effects of Tafamidis on Cardiac Remodelling in Transthyretin Amyloid Cardiomyopathy: Evidence From Contemporary Imaging Data

Tameem Quader iD, Krisha Patel iD, James Sindone, Shaun Khanna iD, Aditya Bhat, Henry Chen, Gary Gan iD, Nitesh Nerlekar iD, Suzanne Eshoo iD, Nicole Bart, Liza Thomas iD, Andrew Sindone iD

European Journal of Clinical Investigation · 2026-08 · 56 (8)

DOI: 10.1111/eci.70246 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 12.08.2026. Verfasst von Tameem Quader und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Blacktown Hospital, New South Wales, Australia. Hauptthemen laut MEDLINE: Ventricular Remodeling, Benzoxazoles, Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tafamidis is the only approved disease‐modifying therapy for transthyretin amyloid cardiomyopathy (ATTR‐CM) in Australia. Although its clinical efficacy is established, its effects on cardiac remodelling assessed by contemporary multimodality imaging remain incompletely defined.

Methods

MEDLINE, Embase and Cochrane databases were systematically searched from 2000 to 2025. Observational studies evaluating tafamidis‐treated versus untreated/control patients that reported serial TTE, CMR or bone‐tracer scintigraphy measurements were eligible. Change‐from‐baseline values were used to derive measures. Outcomes were pooled as standardised mean differences (SMDs) with 95% confidence intervals using random‐effects modelling. A two‐sided p < 0.05 was considered statistically significant.

Results

Over a mean follow‐up of 16 months, tafamidis was associated with significant improvements in left atrial reservoir strain (LASr) (SMD +0.58, 95% CI +0.27 to +0.89; p < 0.001; I 2 = 0) on TTE and right ventricular ejection fraction (RVEF) (SMD +0.51, 95% CI +0.16 to +0.86; p = 0.004; I 2 = 0) on CMR. A reduction in left atrial volume index (LAVi) was observed (SMD –0.24, 95% CI –0.46 to −0.02; p = 0.034; I 2 = 0) on TTE. No consistent effects were seen for LV parameters including LVEF, LV‐GLS, LV mass index, wall thickness, diastolic indices, pulmonary pressures, tissue characterisation markers (native T1, ECV), or H/CL ratio, despite trends toward benefit in some.

Conclusions

Tafamidis demonstrates selective remodelling effects in ATTR‐CM, with the most benefits noted in left atrial function and RV systolic performance, rather than LV structural or functional parameters. Imaging parameters such as LASr, LAVi, and RVEF may serve as sensitive endpoints of therapeutic response in future clinical trials, offering mechanistic insights beyond conventional LV metrics. Study Registration PROSPERO CRD420251145891.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ventricular RemodelingBenzoxazolesAmyloid Neuropathies, FamilialCardiomyopathiesHumansStroke VolumeEchocardiographyMagnetic Resonance Imaging

Stichwörter der Autor:innen

Tafamidisbone‐tracer cardiac scintigraphycardiac magnetic resonanceechocardiographytransthyretin amyloid cardiomyopathy

Substanzen

Benzoxazolestafamidis

Autor:innen und Institutionen

  • Department of Cardiology, Blacktown Hospital, New South Wales, Australia.
  • School of Medicine, Western Sydney University, New South Wales, Australia.
  • Department of Cardiology, Royal Prince Alfred Hospital, New South Wales, Australia.
  • Department of Cardiology, Orange Health Service, New South Wales, Australia.
  • Cardiovascular Program, The George Institute for Global Health, New South Wales, Australia.
  • Department of Cardiology, Westmead Hospital, New South Wales, Australia.

ORCID-Profile: Tameem Quader, Krisha Patel, Shaun Khanna, Gary Gan, Nitesh Nerlekar, Suzanne Eshoo, Liza Thomas, Andrew Sindone

Zitieren

APA

Quader, T., Patel, K., Sindone, J., Khanna, S., Bhat, A., Chen, H., Gan, G., Nerlekar, N., Eshoo, S., Bart, N., Thomas, L., & Sindone, A. (2026). Differential Effects of Tafamidis on Cardiac Remodelling in Transthyretin Amyloid Cardiomyopathy: Evidence From Contemporary Imaging Data. European Journal of Clinical Investigation, 56(8). https://doi.org/10.1111/eci.70246

Vancouver

Quader T, Patel K, Sindone J, Khanna S, Bhat A, Chen H, et al. Differential Effects of Tafamidis on Cardiac Remodelling in Transthyretin Amyloid Cardiomyopathy: Evidence From Contemporary Imaging Data. European Journal of Clinical Investigation. 2026;56(8). doi:10.1111/eci.70246

BibTeX
@article{Quader2026,
  author = {Quader, Tameem and Patel, Krisha and Sindone, James and Khanna, Shaun and Bhat, Aditya and Chen, Henry and Gan, Gary and Nerlekar, Nitesh and Eshoo, Suzanne and Bart, Nicole and Thomas, Liza and Sindone, Andrew},
  title = {Differential Effects of Tafamidis on Cardiac Remodelling in Transthyretin Amyloid Cardiomyopathy: Evidence From Contemporary Imaging Data},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  volume = {56},
  number = {8},
  doi = {10.1111/eci.70246}
}
Kostenlos starten →